
Heart failure with preserved ejection fraction (HFpEF) - Pipeline Insight, 2025
Description
DelveInsight’s, “Heart failure with preserved ejection fraction (HFpEF) - Pipeline Insight, 2025,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Heart failure with preserved ejection fraction (HFpEF) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Heart failure with preserved ejection fraction (HFpEF): Overview
Heart failure with preserved ejection fraction (HFpEF)) occurs when the lower left chamber (left ventricle) is not able to fill properly with blood during the diastolic (filling) phase. The amount of blood pumped out to the body is less than normal. It is also called diastolic heart failure. The types of heart failure are based on a measurement called the ejection fraction. The ejection fraction measures how much blood inside the ventricle is pumped out with each contraction. The left ventricle squeezes and pumps some (but not all) of the blood in the ventricle out to your body. A normal ejection fraction is more than 55%. This means that 55% of the total blood in the left ventricle is pumped out with each heartbeat. Heart failure with preserved ejection fraction (HFpEF)) happens when the left ventricle is not filling with blood as well as normal. The ventricle can pump well. But it may be stiff so it cannot relax and fill with blood as well as normal. The ejection fraction is 50% or more. HFpEF may also be diagnosed if the ejection fraction is 40% to 49%.footnote
""Heart failure with preserved ejection fraction (HFpEF) - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Heart failure with preserved ejection fraction (HFpEF) pipeline landscape is provided which includes the disease overview and Heart failure with preserved ejection fraction (HFpEF) treatment guidelines. The assessment part of the report embraces, in depth Heart failure with preserved ejection fraction (HFpEF) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Heart failure with preserved ejection fraction (HFpEF) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Heart failure with preserved ejection fraction (HFpEF) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Heart failure with preserved ejection fraction (HFpEF) Emerging Drugs
Further product details are provided in the report……..
Heart failure with preserved ejection fraction (HFpEF): Therapeutic Assessment
This segment of the report provides insights about the different Heart failure with preserved ejection fraction (HFpEF) drugs segregated based on following parameters that define the scope of the report, such as:
Heart failure with preserved ejection fraction (HFpEF): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Heart failure with preserved ejection fraction (HFpEF) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heart failure with preserved ejection fraction (HFpEF) drugs.
Heart failure with preserved ejection fraction (HFpEF) Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Heart failure with preserved ejection fraction (HFpEF): Overview
Heart failure with preserved ejection fraction (HFpEF)) occurs when the lower left chamber (left ventricle) is not able to fill properly with blood during the diastolic (filling) phase. The amount of blood pumped out to the body is less than normal. It is also called diastolic heart failure. The types of heart failure are based on a measurement called the ejection fraction. The ejection fraction measures how much blood inside the ventricle is pumped out with each contraction. The left ventricle squeezes and pumps some (but not all) of the blood in the ventricle out to your body. A normal ejection fraction is more than 55%. This means that 55% of the total blood in the left ventricle is pumped out with each heartbeat. Heart failure with preserved ejection fraction (HFpEF)) happens when the left ventricle is not filling with blood as well as normal. The ventricle can pump well. But it may be stiff so it cannot relax and fill with blood as well as normal. The ejection fraction is 50% or more. HFpEF may also be diagnosed if the ejection fraction is 40% to 49%.footnote
""Heart failure with preserved ejection fraction (HFpEF) - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Heart failure with preserved ejection fraction (HFpEF) pipeline landscape is provided which includes the disease overview and Heart failure with preserved ejection fraction (HFpEF) treatment guidelines. The assessment part of the report embraces, in depth Heart failure with preserved ejection fraction (HFpEF) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Heart failure with preserved ejection fraction (HFpEF) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Heart failure with preserved ejection fraction (HFpEF) R&D. The therapies under development are focused on novel approaches to treat/improve Heart failure with preserved ejection fraction (HFpEF).
This segment of the Heart failure with preserved ejection fraction (HFpEF) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Heart failure with preserved ejection fraction (HFpEF) Emerging Drugs
- Tirzepatide: Eli Lilly and Company
- Semaglutide: Novo Nordisk A/S
Further product details are provided in the report……..
Heart failure with preserved ejection fraction (HFpEF): Therapeutic Assessment
This segment of the report provides insights about the different Heart failure with preserved ejection fraction (HFpEF) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Heart failure with preserved ejection fraction (HFpEF)
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Heart failure with preserved ejection fraction (HFpEF): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Heart failure with preserved ejection fraction (HFpEF) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heart failure with preserved ejection fraction (HFpEF) drugs.
Heart failure with preserved ejection fraction (HFpEF) Report Insights
- Heart failure with preserved ejection fraction (HFpEF) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Heart failure with preserved ejection fraction (HFpEF) drugs?
- How many Heart failure with preserved ejection fraction (HFpEF) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Heart failure with preserved ejection fraction (HFpEF)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Heart failure with preserved ejection fraction (HFpEF) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Heart failure with preserved ejection fraction (HFpEF) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Eli Lilly and Company
- Novo Nordisk
- Actelion Pharmaceuticals
- AstraZeneca
- Palatin Technologies
- MyoKardia, Inc.
- Stealth BioTherapeutics Inc.
- Pfizer
- Asklepios Biopharmaceutical, Inc.
- Cardiol Therapeutics
- Gilead Sciences
- Bayer
- Tenaya Therapeutics
- Tirzepatide
- Semaglutide
- Macitentan
- AZD4831
- Dapagliflozin
- PL-3994
- Mavacamten
- elamipretide
- Sildenafil
- NAN-101
- CardiolRx™100
- Ranolazine hydrochloride
- Empagliflozin
- Finerenone
- TYA 11631
Table of Contents
50 Pages
- Introduction
- Executive Summary
- Heart failure with preserved ejection fraction (HFpEF): Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Heart failure with preserved ejection fraction (HFpEF) – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Late Stage Products (Phase III)
- Comparative Analysis
- Tirzepatide: Eli Lilly and Company
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- PL-3994: Palatin Technologies
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- TYA 11631: Tenaya Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Heart failure with preserved ejection fraction (HFpEF) Key Companies
- Heart failure with preserved ejection fraction (HFpEF) Key Products
- Heart failure with preserved ejection fraction (HFpEF)- Unmet Needs
- Heart failure with preserved ejection fraction (HFpEF)- Market Drivers and Barriers
- Heart failure with preserved ejection fraction (HFpEF)- Future Perspectives and Conclusion
- Heart failure with preserved ejection fraction (HFpEF) Analyst Views
- Heart failure with preserved ejection fraction (HFpEF) Key Companies
- Appendix
- Introduction
- Executive Summary
- Heart failure with preserved ejection fraction (HFpEF): Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Heart failure with preserved ejection fraction (HFpEF) – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Heart failure with preserved ejection fraction (HFpEF) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Heart failure with preserved ejection fraction (HFpEF) Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- Tirzepatide: Eli Lilly and Company
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- PL-3994: Palatin Technologies
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- TYA 11631: Tenaya Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Heart failure with preserved ejection fraction (HFpEF) Key Companies
- Heart failure with preserved ejection fraction (HFpEF) Key Products
- Heart failure with preserved ejection fraction (HFpEF)- Unmet Needs
- Heart failure with preserved ejection fraction (HFpEF)- Market Drivers and Barriers
- Heart failure with preserved ejection fraction (HFpEF)- Future Perspectives and Conclusion
- Heart failure with preserved ejection fraction (HFpEF) Analyst Views
- Heart failure with preserved ejection fraction (HFpEF) Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.